Alan Horwich

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma
    A Horwich
    Division of Radiotherapy and Imaging, The Institute of Cancer Research and Urological Oncology Unit, The Royal Marsden NHS Trust, Sutton, UK
    Ann Oncol 24:2104-7. 2013
  2. doi request reprint Prostate cancer: ESMO Consensus Conference Guidelines 2012
    A Horwich
    Department of Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK
    Ann Oncol 24:1141-62. 2013
  3. ncbi request reprint A randomised trial of accelerated radiotherapy for localised invasive bladder cancer
    Alan Horwich
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust, The Institute of Cancer Research, Sutton SM2 5PT, UK
    Radiother Oncol 75:34-43. 2005
  4. ncbi request reprint Testicular germ-cell cancer
    Alan Horwich
    Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK
    Lancet 367:754-65. 2006
  5. pmc Second primary breast cancer after Hodgkin's disease
    A Horwich
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 90:294-8. 2004
  6. doi request reprint Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study
    Roy Vergis
    Institute of Cancer Research, Sutton, UK
    Lancet Oncol 9:342-51. 2008
  7. ncbi request reprint Prostate-specific antigen velocity in untreated, localized prostate cancer
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    BJU Int 101:161-4. 2008
  8. doi request reprint Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation
    Roy Vergis
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    Int J Radiat Oncol Biol Phys 78:35-41. 2010
  9. doi request reprint Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time
    Michael K Ng
    Academic Unit Urology, Royal Marsden Hospital, Sutton, UK
    BJU Int 103:872-6. 2009
  10. doi request reprint Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    J Clin Oncol 29:4096-104. 2011

Detail Information

Publications52

  1. doi request reprint Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma
    A Horwich
    Division of Radiotherapy and Imaging, The Institute of Cancer Research and Urological Oncology Unit, The Royal Marsden NHS Trust, Sutton, UK
    Ann Oncol 24:2104-7. 2013
    ..Extended field radiotherapy is a standard of care for low volume stage II testicular seminoma. We hypothesized that neoadjuvant carboplatin might reduce the recurrence risk...
  2. doi request reprint Prostate cancer: ESMO Consensus Conference Guidelines 2012
    A Horwich
    Department of Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK
    Ann Oncol 24:1141-62. 2013
    ..The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update...
  3. ncbi request reprint A randomised trial of accelerated radiotherapy for localised invasive bladder cancer
    Alan Horwich
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust, The Institute of Cancer Research, Sutton SM2 5PT, UK
    Radiother Oncol 75:34-43. 2005
    ..To evaluate the efficacy and toxicity of an accelerated fractionation regimen to treat localised muscle invasive bladder cancer...
  4. ncbi request reprint Testicular germ-cell cancer
    Alan Horwich
    Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK
    Lancet 367:754-65. 2006
    ..We summarise advances in the understanding and management of TGCT during the past decade...
  5. pmc Second primary breast cancer after Hodgkin's disease
    A Horwich
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 90:294-8. 2004
    ..In this minireview, we examine the evidence which should inform such a management policy...
  6. doi request reprint Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study
    Roy Vergis
    Institute of Cancer Research, Sutton, UK
    Lancet Oncol 9:342-51. 2008
    ..We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically...
  7. ncbi request reprint Prostate-specific antigen velocity in untreated, localized prostate cancer
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    BJU Int 101:161-4. 2008
    ....
  8. doi request reprint Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation
    Roy Vergis
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    Int J Radiat Oncol Biol Phys 78:35-41. 2010
    ..We analyzed tumor expression of apoptotic markers with respect to outcome in men with localized prostate cancer in two randomized controlled trials of radiotherapy dose escalation...
  9. doi request reprint Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time
    Michael K Ng
    Academic Unit Urology, Royal Marsden Hospital, Sutton, UK
    BJU Int 103:872-6. 2009
    ....
  10. doi request reprint Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    J Clin Oncol 29:4096-104. 2011
    ..We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any yet published, to our knowledge...
  11. doi request reprint Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance
    Nicholas J van As
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Surrey, United Kingdom
    Eur Urol 54:1297-305. 2008
    ..Outcome data from a prospective study of active surveillance of localised prostate cancer were analysed to identify factors, present at the time of diagnosis, that predict subsequent radical treatment...
  12. ncbi request reprint Efficacy of low-dose dexamethasone in castration-refractory prostate cancer
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    BJU Int 101:440-3. 2008
    ....
  13. ncbi request reprint Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer
    Vedang Murthy
    Academic Unit of Radiotherapy and Oncology, and Department of Computing and Information, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Surrey, UK
    BJU Int 97:476-9. 2006
    ..To prospectively evaluate the time-course of recovery of serum testosterone levels after a short course of luteinizing hormone-releasing hormone analogue (LHRHa) and radical radiotherapy to the prostate...
  14. pmc Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:1116-21. 2009
    ..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
  15. pmc Identification of new genetic risk factors for prostate cancer
    Michelle Guy
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Asian J Androl 11:49-55. 2009
    ..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
  16. ncbi request reprint Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)
    Bhawna Sirohi
    Lymphoma Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Hematology 12:149-53. 2007
    ..04). GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes...
  17. doi request reprint Diethylstilbestrol in castration-resistant prostate cancer
    Anna Wilkins
    Academic Urology Unit, Royal Marsden Hospital, Sutton, UK
    BJU Int 110:E727-35. 2012
    ..The most important toxicity was thromboembolism in 10% of men. Overall the drug has an acceptable toxicity profile and offers a palliative benefit in frail elderly men who may not be fit for chemotherapy...
  18. doi request reprint Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 30:2745-52. 2012
    ....
  19. doi request reprint Clinical implications of introducing a new PSA assay
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Int Urol Nephrol 40:657-61. 2008
    ..The availability of two assays in the same laboratory provided an opportunity to audit the clinical implications of the interassay variation in PSA levels...
  20. ncbi request reprint Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy
    Duncan C Gilbert
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    BJU Int 98:67-9. 2006
    ..To estimate the rate of relapse in men with stage I nonseminomatous germ cell tumours (NSGCT) of the testis treated with one cycle of chemotherapy instead of the usual two cycles...
  21. ncbi request reprint Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease
    Mehdi Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, UK
    Radiother Oncol 78:1-5. 2006
    ..There is yet no consensus regarding the appropriate radiotherapy portal following chemotherapy. A good guide to the adjuvant radiotherapy field is the site of relapse in patients treated with chemotherapy alone...
  22. doi request reprint Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study
    Vedang Murthy
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust, Surrey, UK
    Clin Lymphoma Myeloma 8:241-5. 2008
    ..To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma...
  23. ncbi request reprint Outcome of early detection and radiotherapy for occult spinal cord compression
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    Radiother Oncol 85:469-72. 2007
    ..Thus MRI surveillance for SCC may be important for prostate cancer patients with bone metastases...
  24. ncbi request reprint Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Natl Cancer Inst 99:206-14. 2007
    ....
  25. ncbi request reprint Technological advances in radiotherapy for the treatment of localised prostate cancer
    Stephen A Mangar
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5NG, UK
    Eur J Cancer 41:908-21. 2005
    ....
  26. pmc Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
    Zsofia Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 43:785-91. 2011
    ..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
  27. doi request reprint Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer
    Susan Lalondrelle
    Academic Urology Unit, Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, UK
    Int J Radiat Oncol Biol Phys 79:705-12. 2011
    ..To examine patterns of bladder wall motion during high-dose hypofractionated bladder radiotherapy and to validate a novel adaptive planning method, A-POLO, to prevent subsequent geographic miss...
  28. doi request reprint Minimizing toxicity in early-stage testicular cancer treatment
    Mausam Singhera
    Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Rev Anticancer Ther 12:185-93. 2012
    ..This article details the toxicities associated with the diagnosis and treatments of early-stage testicular cancer and current strategies used to minimize toxicity while retaining the excellent cure rates...
  29. ncbi request reprint Predictors of histological disease progression in untreated, localized prostate cancer
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    J Urol 178:833-7. 2007
    ..There is no consensus on the need for or optimum timing of repeat biopsies as part of active surveillance...
  30. ncbi request reprint Early outcomes of active surveillance for localized prostate cancer
    Claire Hardie
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
    BJU Int 95:956-60. 2005
    ....
  31. ncbi request reprint Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer
    Stephen A Mangar
    Department of Radiotherapy, Hammersmith Hospital NHS Trust, London, UK
    Radiother Oncol 85:207-14. 2007
    ..To assess the feasibility of using cine-MR to study intra-fractional time-volume and volume-deformity patterns of the bladder during radiotherapy as initial methodology for Predictive Organ Localization (POLO)...
  32. doi request reprint Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, UK
    Nat Genet 45:385-91, 391e1-2. 2013
    ..7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies...
  33. ncbi request reprint Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management
    Mehdi Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Cancer 95:520-30. 2002
    ..The time-course of recurrence has implications for the duration of follow-up. This study was undertaken to assess the risk and time-course of recurrence and to identify patients at higher risk of late recurrence...
  34. ncbi request reprint The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours
    Ramachandran Venkitaraman
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    BJU Int 100:30-2. 2007
    ....
  35. doi request reprint The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer
    Gary J R Cook
    Department of Nuclear Medicine and PET, Royal Marsden Hospital, Downs Rd, Sutton, Surrey, SM2 5PT, UK
    Eur J Nucl Med Mol Imaging 38:7-13. 2011
    ..We hypothesised that a flare reaction might amplify the signal from subclinical SM, increasing the sensitivity of BS and that the phenomenon may be specific for metastases...
  36. pmc Prospective study of factors predicting adherence to medical advice in men with testicular cancer
    Clare Moynihan
    Academic Radiotherapy Unit, The Institute of Cancer Research and Department of Clinical Research Development, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 27:2144-50. 2009
    ..The nonadherence end point (nonattender) was two failures to attend an outpatient appointment at least 1 month apart, despite a written reminder...
  37. ncbi request reprint The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation
    Chris Parker
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
    Int J Radiat Oncol Biol Phys 58:53-8. 2004
    ..Serum hemoglobin level (Hb) is a significant determinant of treatment outcome after radical radiotherapy (RT) for several cancer types, but its importance in prostate cancer is not well established...
  38. pmc Primary Adult Renal Ewing's Sarcoma: A Rare Entity
    Ravindra Mukkunda
    Urology Unit, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Sarcoma 2009:504654. 2009
    ..Radical nephrectomy with adjuvant combination chemotherapy produced the best results but the outlook remained poor with only one patient experiencing long disease-free survival...
  39. ncbi request reprint Adjuvant chemotherapy for high-risk low-stage germ-cell tumours
    Alan Horwich
    The Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, Surrey UK
    Curr Opin Urol 12:431-4. 2002
    ..To review the assessment and management of early germ-cell tumours...
  40. doi request reprint Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
  41. ncbi request reprint Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses
    William F Hendry
    Academic Department of Urology, The Royal Marsden National Health Service Trust and Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer 94:1668-76. 2002
    ..A retrospective analysis was undertaken to define the outcome in these two groups of patients...
  42. ncbi request reprint Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:4448-52. 2002
    ..We performed a pooled analysis of patients from the four largest surveillance studies to better delineate prognostic factors associated with disease progression...
  43. ncbi request reprint Extragonadal germ cell tumors: relation to testicular neoplasia and management options
    Carsten Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    APMIS 111:49-59; discussion 59-63. 2003
    ..Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%...
  44. ncbi request reprint Radiotherapy in stage I seminoma of the testis
    Alan Horwich
    J Clin Oncol 22:585-8. 2004
  45. ncbi request reprint Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)
    William G Jones
    Cookridge Hospital, Leeds, United Kingdom
    J Clin Oncol 23:1200-8. 2005
    ..To assess the possibility of reducing radiotherapy doses without compromising efficacy in the management of patients with stage I seminoma...
  46. ncbi request reprint Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis
    Carsten Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 20:1864-73. 2002
    ..To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies...
  47. ncbi request reprint Guidelines on testicular cancer
    Peter Albers
    Department of Urology, Klinikum Kassel GmbH Mönchebergstr 41 43, Kassel, Germany
    Eur Urol 48:885-94. 2005
    ..To up-date the 2001 version of the EAU testicular cancer guidelines...
  48. ncbi request reprint Stage I seminoma
    Alan Horwich
    Onkologie 29:554-5. 2006
  49. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:497-513. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
  50. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:478-96. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
  51. ncbi request reprint Bleomycin and scuba diving: where is the harm?
    Ronald de Wit
    Erasmus University Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 8:954-5. 2007
  52. ncbi request reprint Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
    Hendrik Tobias Arkenau
    Haematologica 92:271-2. 2007
    ..Three patients (19%) achieved a complete remission and eight (50%) a partial remission. GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL...